In fact, PMIBcr/Abl-R6 showed a significant efficacy in various primary samples isolated from patients with CML and acute lymphoblastic leukemia (ALL), in association with Bcr/Abl degradation and p53 activation (Ma et al., 2022a). The gene discussed is BCR; the disease is acute lymphoblastic leukemia.